HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

FDA hearing on Amgen's Tavneos will include findings from an independent review

An independent research firm is reviewing data on Amgen's Tavneos as the company prepares for a hearing with the FDA which could determine whether the rare disease treatment remains on the market.

By FiercePharma · Jun 14, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Regulatory tracker: Novo's oral GLP-1 picks up UK approval
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
Jun 14, 2026
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFierceBiotech ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 14, 2026
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
The WeekBriefing
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…
Jun 14, 2026